Debut Pop Fades

The stock gives back part of its 18% first-day gain as IPO flipping, valuation discipline, and the absence of near-term clinical catalysts weigh on trading. This is a common outcome for biotech IPOs that price well but remain years from commercial revenue.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.